PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS
PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS
复制标题
DOI：
10.1016/s0149-2918(05)80001-3
复制
发表时间：
1980-01-01
影响因子：
5.9
通讯作者：
SKEEL, RT
中科院分区：
文献类型：
--
作者：
DEWYS, WD;BEGG, C;SKEEL, RT
使用12种化疗方案中3047例患者的数据分析了化疗前体重减轻的预后影响。体重减轻的频率范围从良性非霍奇金淋巴瘤的31%到胃癌的87%。与体重未减轻的患者相比，9种方案中体重减轻的患者的中位生存期显著缩短。化疗反应率在体重减轻的患者中较低，但只有在乳腺癌患者中这种差异才有意义。除胰腺癌和胃癌患者外，体重下降与体能状态下降相关。在体能状态分类中，体重减轻与中位生存期降低相关。体重减轻的频率随着转移灶累及解剖部位的增加而增加，但在解剖部位受累的类别中，体重减轻与中位生存期降低相关。这些观察结果强调了体重减轻的预后作用，特别是在具有良好的体能状态或肿瘤解剖受累有限的患者中。
The prognostic effect of weight loss prior to chemotherapy was analyzed using data from 3047 patients enrolled in 12 chemotherapy protocols. The frequency of weight loss ranged from 31% for favorable non-Hodgkin''s lymphoma to 87% in gastric cancer. Median survival was significantly shorter in 9 protocols for the patients with weight loss compared to the patients with no weight loss. Chemotherapy response rates were lower in the patients with weight loss, but only in patients with breast cancer was this difference significant. Decreasing weight was correlated with decreasing performance status except for patients with pancreatic and gastric cancer. Within performance status categories, weight loss was associated with decreased median survival. The frequency of weight loss increased with increasing number of anatomic sites involved with metastases, but within categories of anatomic involvement, weight loss was associated with decreased median survival. These observations emphasize the prognostic effect of weight loss, especially in patients with a favorable performance status or a limited anatomic involvement with tumor.